s6y

Universe Pharmaceuticals INC

Ticker
UPC
CIK
1809616
Industry
Pharmaceutical Preparations

Financials 2

  1. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Sep 30, 2024
  2. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Sep 30, 2022

Ownership 10

  1. 4 Statement of changes in beneficial ownership of securities
  2. 3 Initial statement of beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. 3 Initial statement of beneficial ownership of securities
  7. 3 Initial statement of beneficial ownership of securities
  8. SC 13G/A Major Shareholders
  9. SC 13G Major Shareholders
  10. SC 13G Major Shareholders

Prospectus 10

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  3. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  4. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  5. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  6. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  7. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  8. DRSLTR Correspondence Related to Draft Registration Statement
  9. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  10. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Other 97

  1. EFFECT Notice of Effectiveness
  2. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  3. F-3 Registration statement for specified transactions by certain foreign private issuers
  4. 6-K/A Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  5. SCHEDULE 13G
  6. SCHEDULE 13G
  7. SCHEDULE 13G
  8. SCHEDULE 13G
  9. SCHEDULE 13G
  10. SCHEDULE 13G

All 97 other filings